{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "24",
                "@timestamp": "2023-03-24T05:23:17.000017-04:00",
                "@year": "2023",
                "@month": "03"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2023",
                "@month": "01"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": {
                "xocs:funding-agency-matched-string": "National Research Council of Thailand",
                "xocs:funding-agency-acronym": "NRCT",
                "xocs:funding-agency": "National Research Council of Thailand",
                "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100004704",
                "xocs:funding-agency-country": "http://sws.geonames.org/1605651/"
            },
            "xocs:funding-addon-generated-timestamp": "2022-12-14T05:04:17.995Z",
            "xocs:funding-text": "The current study was funded by the National Research Council of Thailand (NRCT).",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "postal-code": "10330",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Division of Nephrology"},
                                {"$": "Department of Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"},
                                {"$": "King Chulalongkorn Memorial Hospital"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "103183427"
                                },
                                {"@afid": "60022183"},
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-944677102-d60f1841c38b16ae2d8877dce924bbdf-1",
                            "ce:source-text": "Division of Nephrology Department of Medicine Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital",
                            "@dptid": "103183427"
                        },
                        "author": [
                            {
                                "ce:given-name": "Natavudh",
                                "preferred-name": {
                                    "ce:given-name": "Natavudh",
                                    "ce:initials": "N.",
                                    "ce:surname": "Townamchai",
                                    "ce:indexed-name": "Townamchai N."
                                },
                                "@author-instance-id": "OB2BibRecID-944677102-db7bff387f7e307e5e7de0e6d5c9cf74-1",
                                "@seq": "1",
                                "ce:initials": "N.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Townamchai",
                                "@auid": "24588157900",
                                "ce:indexed-name": "Townamchai N."
                            },
                            {
                                "ce:given-name": "Yingyos",
                                "preferred-name": {
                                    "ce:given-name": "Yingyos",
                                    "ce:initials": "Y.",
                                    "ce:surname": "Avihingsanon",
                                    "ce:indexed-name": "Avihingsanon Y."
                                },
                                "@author-instance-id": "OB2BibRecID-944677102-aa57284b729807d615c71b4feba4f726-1",
                                "@seq": "2",
                                "ce:initials": "Y.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Avihingsanon",
                                "@auid": "57194864874",
                                "ce:indexed-name": "Avihingsanon Y."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "organization": [
                                {"$": "Renal Immunology and Renal Transplant Research Unit"},
                                {"$": "Department of Medicine"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "103183427"
                                },
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-944677102-332720b33c23e919a65eba2b5086e998-1",
                            "ce:source-text": "Renal Immunology and Renal Transplant Research Unit Department of Medicine Faculty of Medicine Chulalongkorn University",
                            "@dptid": "103183427"
                        },
                        "author": [
                            {
                                "ce:given-name": "Natavudh",
                                "preferred-name": {
                                    "ce:given-name": "Natavudh",
                                    "ce:initials": "N.",
                                    "ce:surname": "Townamchai",
                                    "ce:indexed-name": "Townamchai N."
                                },
                                "@author-instance-id": "OB2BibRecID-944677102-db7bff387f7e307e5e7de0e6d5c9cf74-1",
                                "@seq": "1",
                                "ce:initials": "N.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Townamchai",
                                "@auid": "24588157900",
                                "ce:indexed-name": "Townamchai N."
                            },
                            {
                                "ce:given-name": "Yingyos",
                                "preferred-name": {
                                    "ce:given-name": "Yingyos",
                                    "ce:initials": "Y.",
                                    "ce:surname": "Avihingsanon",
                                    "ce:indexed-name": "Avihingsanon Y."
                                },
                                "@author-instance-id": "OB2BibRecID-944677102-aa57284b729807d615c71b4feba4f726-1",
                                "@seq": "2",
                                "ce:initials": "Y.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Avihingsanon",
                                "@auid": "57194864874",
                                "ce:indexed-name": "Avihingsanon Y."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Excellence Center for Solid Organ Transplantation"},
                                {"$": "King Chulalongkorn Memorial Hospital"},
                                {"$": "The Thai Red Cross Society"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60022183",
                                    "@dptid": "114274356"
                                },
                                {"@afid": "60031780"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-944677102-92d83f741dd6e9880bc4556dc142ed65-1",
                            "ce:source-text": "Excellence Center for Solid Organ Transplantation King Chulalongkorn Memorial Hospital The Thai Red Cross Society Bangkok Thailand",
                            "@dptid": "114274356"
                        },
                        "author": [
                            {
                                "ce:given-name": "Natavudh",
                                "preferred-name": {
                                    "ce:given-name": "Natavudh",
                                    "ce:initials": "N.",
                                    "ce:surname": "Townamchai",
                                    "ce:indexed-name": "Townamchai N."
                                },
                                "@author-instance-id": "OB2BibRecID-944677102-db7bff387f7e307e5e7de0e6d5c9cf74-1",
                                "@seq": "1",
                                "ce:initials": "N.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Townamchai",
                                "@auid": "24588157900",
                                "ce:indexed-name": "Townamchai N."
                            },
                            {
                                "ce:given-name": "Yingyos",
                                "preferred-name": {
                                    "ce:given-name": "Yingyos",
                                    "ce:initials": "Y.",
                                    "ce:surname": "Avihingsanon",
                                    "ce:indexed-name": "Avihingsanon Y."
                                },
                                "@author-instance-id": "OB2BibRecID-944677102-aa57284b729807d615c71b4feba4f726-1",
                                "@seq": "2",
                                "ce:initials": "Y.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Avihingsanon",
                                "@auid": "57194864874",
                                "ce:indexed-name": "Avihingsanon Y."
                            }
                        ]
                    }
                ],
                "citation-title": "Updated management for antibody-mediated rejection: Opportunity to prolong kidney allograft survival",
                "abstracts": "© 2023 Lippincott Williams and Wilkins. All rights reserved.Purpose of reviewAntibody-mediated rejection (ABMR) is an important barrier to achieve long-term kidney allograft survival. Human leukocyte antibody (HLA)-incompatibility and ABO-incompatibility are the two main mechanisms of ABMR. Nevertheless, the advances in managing ABMR have changed the paradigm for kidney transplantation. This review aimed to emphasize the HLA-incompatibility and ABO-incompatibility kidney transplant and update the management of ABMR.Recent findingsHLA-incompatibility kidney transplantation is a strong risk factor for ABMR. Donor-specific antibody (DSA) is a surrogate biomarker that prevents long-term allograft survival. The standard treatment for ABMR has unfavorable results. New drugs that target the B cell are a promising approach to treat ABMR. In the past, ABO-incompatibility kidney donor was an absolute contraindication but now, it is widely accepted as an alternative organ resource. The advancement of ABO antibody removal and B-cell depletion therapy has been successfully developed. ABO isoagglutination remains the main biomarker for monitoring ABMR during the transplantation process. C4d staining without inflammation of the kidney allograft is the marker for the accommodation process.SummaryWith the shortage of organ donors, transplant experts have expanded the organ resources and learned how to overcome the immunological barriers by using novel biomarkers and developing new treatments that support long-term graft survival.",
                "correspondence": {
                    "affiliation": {
                        "country": "Thailand",
                        "postal-code": "10330",
                        "@country": "tha",
                        "city": "Bangkok",
                        "organization": [
                            {"$": "Division of Nephrology"},
                            {"$": "Department of Medicine"},
                            {"$": "Faculty of Medicine"},
                            {"$": "Chulalongkorn University"},
                            {"$": "King Chulalongkorn Memorial Hospital"}
                        ],
                        "@affiliation-instance-id": "OB2BibRecID-944677102-d60f1841c38b16ae2d8877dce924bbdf-1",
                        "ce:source-text": "Division of Nephrology Department of Medicine Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital"
                    },
                    "person": {
                        "ce:given-name": "Natavudh",
                        "@author-instance-id": "OB2BibRecID-944677102-64bc27771ba8f27b205e99062671927c-1",
                        "ce:initials": "N.",
                        "ce:surname": "Townamchai",
                        "ce:indexed-name": "Townamchai N."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "ABO incompatibility",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "antibody-mediated rejection",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "antihuman leukocyte antigen",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "donor-specific antihuman leukocyte antibody",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "re"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://journals.lww.com/co-nephrolhypertens/pages/default.aspx",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Current Opinion in Nephrology and Hypertension",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "32",
                            "@issue": "1"
                        },
                        "pagerange": {
                            "@first": "13",
                            "@last": "19"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Current Opinion in Nephrology and Hypertension",
                    "publicationdate": {
                        "month": "01",
                        "year": "2023",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "1 January 2023"
                        },
                        "day": "01"
                    },
                    "codencode": "CNHYE",
                    "sourcetitle-abbrev": "Curr. Opin. Nephrol. Hypertens.",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "14736543",
                            "@type": "electronic"
                        },
                        {
                            "$": "10624821",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "Lippincott Williams and Wilkins"},
                    "@srcid": "19849"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "25",
                                    "classification-description": "Hematology"
                                },
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                },
                                {
                                    "classification-code": "28",
                                    "classification-description": "Urology and Nephrology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2700"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": {
                                "cas-registry-number": "1947415-68-0",
                                "chemical-name": "imlifidase"
                            }
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Biomarkers"},
                                {"chemical-name": "Isoantibodies"}
                            ]
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "NURSNG"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "23",
                    "@timestamp": "BST 03:26:08",
                    "@year": "2023",
                    "@month": "03"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2021579078",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "639285778",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "944677102",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20221116052",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "36250450",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "2022517004",
                            "@idtype": "NURSNG"
                        },
                        {
                            "$": "20223573433",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20224326328",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2022903398306X",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85142940973",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85142940973",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "639285778",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "76885399",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1097/MNH.0000000000000843"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "43",
                "reference": [
                    {
                        "ref-fulltext": "Lohéac C, Aubert O, Loupy A, Legendre C,. Identifying the specific causes of kidney allograft loss: a population-based study. Nephrol Ther 2018; 14: (Suppl 1): S39-S50.",
                        "@reference-instance-id": "OB2BibRecID-944677102-2166eb9081812a3ba958fad50ab7f1d8-1",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Identifying the specific causes of kidney allograft loss: A population-based study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85044571235",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "S39",
                                    "@last": "S50"
                                }
                            },
                            "ref-text": "Suppl 1",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Lohéac",
                                    "ce:indexed-name": "Loheac C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "O.",
                                    "@_fa": "true",
                                    "ce:surname": "Aubert",
                                    "ce:indexed-name": "Aubert O."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Loupy",
                                    "ce:indexed-name": "Loupy A."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Legendre",
                                    "ce:indexed-name": "Legendre C."
                                }
                            ]},
                            "ref-sourcetitle": "Nephrol Ther"
                        },
                        "ce:source-text": "Lohéac C, Aubert O, Loupy A, Legendre C,. Identifying the specific causes of kidney allograft loss: a population-based study. Nephrol Ther 2018; 14: (Suppl 1): S39-S50."
                    },
                    {
                        "ref-fulltext": "Gosset C, Viglietti D, Rabant M,. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int 2017; 92: 729-742.",
                        "@reference-instance-id": "OB2BibRecID-944677102-50860097584e5bd0c328ec55e4d1bd24-2",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85019960686",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "92"},
                                "pagerange": {
                                    "@first": "729",
                                    "@last": "742"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Gosset",
                                    "ce:indexed-name": "Gosset C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Viglietti",
                                    "ce:indexed-name": "Viglietti D."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Rabant",
                                    "ce:indexed-name": "Rabant M."
                                }
                            ]},
                            "ref-sourcetitle": "Kidney Int"
                        },
                        "ce:source-text": "Gosset C, Viglietti D, Rabant M,. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int 2017; 92: 729-742."
                    },
                    {
                        "ref-fulltext": "Loupy A, Vernerey D, Tinel C,. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26: 1721-1731.",
                        "@reference-instance-id": "OB2BibRecID-944677102-72e58909ddf9d8f564fd02536aaf588a-3",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84934777199",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "26"},
                                "pagerange": {
                                    "@first": "1721",
                                    "@last": "1731"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Loupy",
                                    "ce:indexed-name": "Loupy A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Vernerey",
                                    "ce:indexed-name": "Vernerey D."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Tinel",
                                    "ce:indexed-name": "Tinel C."
                                }
                            ]},
                            "ref-sourcetitle": "J Am Soc Nephrol"
                        },
                        "ce:source-text": "Loupy A, Vernerey D, Tinel C,. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26: 1721-1731."
                    },
                    {
                        "ref-fulltext": "Betjes MGH, Roelen DL, van Agteren M, Kal-van Gestel J,. Causes of kidney graft failure in a cohort of recipients with a very long-time follow-up after transplantation. Front Med (Lausanne) 2022; 9: 842419.",
                        "@reference-instance-id": "OB2BibRecID-944677102-841d6178c107bae370918919ad910f6b-4",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Causes of kidney graft failure in a cohort of recipients with a very long-time follow-up after transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85133357259",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {"@first": "842419"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.G.H.",
                                    "@_fa": "true",
                                    "ce:surname": "Betjes",
                                    "ce:indexed-name": "Betjes M.G.H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Roelen",
                                    "ce:indexed-name": "Roelen D.L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Van Agteren",
                                    "ce:indexed-name": "Van Agteren M."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Kal-Van Gestel",
                                    "ce:indexed-name": "Kal-Van Gestel J."
                                }
                            ]},
                            "ref-sourcetitle": "Front Med (Lausanne)"
                        },
                        "ce:source-text": "Betjes MGH, Roelen DL, van Agteren M, Kal-van Gestel J,. Causes of kidney graft failure in a cohort of recipients with a very long-time follow-up after transplantation. Front Med (Lausanne) 2022; 9: 842419."
                    },
                    {
                        "ref-fulltext": "Orandi BJ, Luo X, Massie AB,. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med 2016; 374: 940-950.",
                        "@reference-instance-id": "OB2BibRecID-944677102-105eb04457f088b2231efa7d5e2272f1-5",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Survival benefit with kidney transplants from HLA-incompatible live donors"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84960466211",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "374"},
                                "pagerange": {
                                    "@first": "940",
                                    "@last": "950"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "B.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Orandi",
                                    "ce:indexed-name": "Orandi B.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "X.",
                                    "@_fa": "true",
                                    "ce:surname": "Luo",
                                    "ce:indexed-name": "Luo X."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Massie",
                                    "ce:indexed-name": "Massie A.B."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Orandi BJ, Luo X, Massie AB,. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med 2016; 374: 940-950."
                    },
                    {
                        "ref-fulltext": "Massie AB, Orandi BJ, Waldram MM,. Impact of ABO-incompatible living donor kidney transplantation on patient survival. Am J Kidney Dis 2020; 76: 616-623.",
                        "@reference-instance-id": "OB2BibRecID-944677102-6d77dce593a3e79d5f373c5639f2d8f9-6",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Impact of ABO-incompatible living donor kidney transplantation on patient survival"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85089102051",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "76"},
                                "pagerange": {
                                    "@first": "616",
                                    "@last": "623"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Massie",
                                    "ce:indexed-name": "Massie A.B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "B.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Orandi",
                                    "ce:indexed-name": "Orandi B.J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Waldram",
                                    "ce:indexed-name": "Waldram M.M."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Kidney Dis"
                        },
                        "ce:source-text": "Massie AB, Orandi BJ, Waldram MM,. Impact of ABO-incompatible living donor kidney transplantation on patient survival. Am J Kidney Dis 2020; 76: 616-623."
                    },
                    {
                        "ref-fulltext": "Wiebe C, Gibson IW, Blydt-Hansen TD,. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.",
                        "@reference-instance-id": "OB2BibRecID-944677102-fb7d835ddaba6b53bd28d27e7b2c655b-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84860473178",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "1157",
                                    "@last": "1167"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Wiebe",
                                    "ce:indexed-name": "Wiebe C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "I.W.",
                                    "@_fa": "true",
                                    "ce:surname": "Gibson",
                                    "ce:indexed-name": "Gibson I.W."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "T.D.",
                                    "@_fa": "true",
                                    "ce:surname": "Blydt-Hansen",
                                    "ce:indexed-name": "Blydt-Hansen T.D."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Wiebe C, Gibson IW, Blydt-Hansen TD,. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167."
                    },
                    {
                        "ref-fulltext": "Vo AA, Aubert O, Haas M,. Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation. Transplantation 2019; 103: 2666-2674.",
                        "@reference-instance-id": "OB2BibRecID-944677102-51f925491b2f9f869721290504e2eabd-8",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85071999046",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "103"},
                                "pagerange": {
                                    "@first": "2666",
                                    "@last": "2674"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Vo",
                                    "ce:indexed-name": "Vo A.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "O.",
                                    "@_fa": "true",
                                    "ce:surname": "Aubert",
                                    "ce:indexed-name": "Aubert O."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Haas",
                                    "ce:indexed-name": "Haas M."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Vo AA, Aubert O, Haas M,. Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation. Transplantation 2019; 103: 2666-2674."
                    },
                    {
                        "ref-fulltext": "Orandi BJ, Garonzik-Wang JM, Massie AB,. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014; 14: 1573-1580.",
                        "@reference-instance-id": "OB2BibRecID-944677102-1c08efa07769a168ef05292a07aa1ab1-9",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Quantifying the risk of incompatible kidney transplantation: A multicenter study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84903137440",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "1573",
                                    "@last": "1580"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "B.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Orandi",
                                    "ce:indexed-name": "Orandi B.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Garonzik-Wang",
                                    "ce:indexed-name": "Garonzik-Wang J.M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Massie",
                                    "ce:indexed-name": "Massie A.B."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Orandi BJ, Garonzik-Wang JM, Massie AB,. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014; 14: 1573-1580."
                    },
                    {
                        "ref-fulltext": "Loupy A, Lefaucheur C, Vernerey D,. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.",
                        "@reference-instance-id": "OB2BibRecID-944677102-4ed104ea501439018d02007b03a48907-10",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Complement-binding anti-HLA antibodies and kidney-allograft survival"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84884505267",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "369"},
                                "pagerange": {
                                    "@first": "1215",
                                    "@last": "1226"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Loupy",
                                    "ce:indexed-name": "Loupy A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Lefaucheur",
                                    "ce:indexed-name": "Lefaucheur C."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Vernerey",
                                    "ce:indexed-name": "Vernerey D."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Loupy A, Lefaucheur C, Vernerey D,. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226."
                    },
                    {
                        "ref-fulltext": "Zhang R,. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol 2018; 13: 182-192.",
                        "@reference-instance-id": "OB2BibRecID-944677102-911c7fcb4441eda4989cf941f08e4e9f-11",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Donor-specific antibodies in kidney transplant recipients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85040223052",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {
                                    "@first": "182",
                                    "@last": "192"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "R.",
                                "@_fa": "true",
                                "ce:surname": "Zhang",
                                "ce:indexed-name": "Zhang R."
                            }]},
                            "ref-sourcetitle": "Clin J Am Soc Nephrol"
                        },
                        "ce:source-text": "Zhang R,. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol 2018; 13: 182-192."
                    },
                    {
                        "ref-fulltext": "Lefaucheur C, Viglietti D, Bentlejewski C,. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2016; 27: 293-304.",
                        "@reference-instance-id": "OB2BibRecID-944677102-c1e31c9b7b4778233f35d4cb652324cb-12",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84954411181",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "27"},
                                "pagerange": {
                                    "@first": "293",
                                    "@last": "304"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Lefaucheur",
                                    "ce:indexed-name": "Lefaucheur C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Viglietti",
                                    "ce:indexed-name": "Viglietti D."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Bentlejewski",
                                    "ce:indexed-name": "Bentlejewski C."
                                }
                            ]},
                            "ref-sourcetitle": "J Am Soc Nephrol"
                        },
                        "ce:source-text": "Lefaucheur C, Viglietti D, Bentlejewski C,. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 2016; 27: 293-304."
                    },
                    {
                        "ref-fulltext": "Friebus-Kardash J, Nela E, Mohlendick B,. Development of de novo donor-specific HLA antibodies and AMR in renal transplant patients depends on CYP3A5 genotype. Transplantation 2022; 106: 1031-1042.",
                        "@reference-instance-id": "OB2BibRecID-944677102-53d891a221261e1d5dd9ac057072190f-13",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Development of de novo donor-specific HLA antibodies and AMR in renal transplant patients depends on CYP3A5 genotype"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85125893276",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "106"},
                                "pagerange": {
                                    "@first": "1031",
                                    "@last": "1042"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Friebus-Kardash",
                                    "ce:indexed-name": "Friebus-Kardash J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Nela",
                                    "ce:indexed-name": "Nela E."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Mohlendick",
                                    "ce:indexed-name": "Mohlendick B."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Friebus-Kardash J, Nela E, Mohlendick B,. Development of de novo donor-specific HLA antibodies and AMR in renal transplant patients depends on CYP3A5 genotype. Transplantation 2022; 106: 1031-1042."
                    },
                    {
                        "ref-fulltext": "Wan SS, Chadban SJ, Watson N, Wyburn K,. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. Am J Transplant 2020; 20: 1351-1364. The study identified the risks of de novo donor-specific antibody and the immunological risk for transplant recipients.",
                        "@reference-instance-id": "OB2BibRecID-944677102-7ffe3b9aac58516486b60ccf29f2dc46-14",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85083812648",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {
                                    "@first": "1351",
                                    "@last": "1364"
                                }
                            },
                            "ref-text": "The study identified the risks of de novo donor-specific antibody and the immunological risk for transplant recipients",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Wan",
                                    "ce:indexed-name": "Wan S.S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Chadban",
                                    "ce:indexed-name": "Chadban S.J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Watson",
                                    "ce:indexed-name": "Watson N."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Wyburn",
                                    "ce:indexed-name": "Wyburn K."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Wan SS, Chadban SJ, Watson N, Wyburn K,. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. Am J Transplant 2020; 20: 1351-1364. The study identified the risks of de novo donor-specific antibody and the immunological risk for transplant recipients."
                    },
                    {
                        "ref-fulltext": "Madariaga HM, Riella LV,. Chronic allograft injury: an overview of pathogenesis and treatment strategies. Contrib Nephrol 2017; 190: 168-180.",
                        "@reference-instance-id": "OB2BibRecID-944677102-d1e8f0fb9c8223352fafb1ae46d5a2f1-15",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Chronic allograft injury: An overview of pathogenesis and treatment strategies"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85020239040",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "190"},
                                "pagerange": {
                                    "@first": "168",
                                    "@last": "180"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Madariaga",
                                    "ce:indexed-name": "Madariaga H.M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.V.",
                                    "@_fa": "true",
                                    "ce:surname": "Riella",
                                    "ce:indexed-name": "Riella L.V."
                                }
                            ]},
                            "ref-sourcetitle": "Contrib Nephrol"
                        },
                        "ce:source-text": "Madariaga HM, Riella LV,. Chronic allograft injury: an overview of pathogenesis and treatment strategies. Contrib Nephrol 2017; 190: 168-180."
                    },
                    {
                        "ref-fulltext": "Schinstock CA, Mannon RB, Budde K,. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation 2020; 104: 911-922.",
                        "@reference-instance-id": "OB2BibRecID-944677102-f70556aeb308fdf4b8be729ef4946d78-16",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 expert consensus from the Transplantation Society Working Group"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85083727228",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "104"},
                                "pagerange": {
                                    "@first": "911",
                                    "@last": "922"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Schinstock",
                                    "ce:indexed-name": "Schinstock C.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Mannon",
                                    "ce:indexed-name": "Mannon R.B."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Budde",
                                    "ce:indexed-name": "Budde K."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Schinstock CA, Mannon RB, Budde K,. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation 2020; 104: 911-922."
                    },
                    {
                        "ref-fulltext": "Lorant T, Bengtsson M, Eich T,. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (Imlifidase) in chronic kidney disease patients. Am J Transplant 2018; 18: 2752-2762.",
                        "@reference-instance-id": "OB2BibRecID-944677102-095d123d97b4146d2935aa874cae5967-17",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (Imlifidase) in chronic kidney disease patients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85045747909",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "18"},
                                "pagerange": {
                                    "@first": "2752",
                                    "@last": "2762"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Lorant",
                                    "ce:indexed-name": "Lorant T."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Bengtsson",
                                    "ce:indexed-name": "Bengtsson M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Eich",
                                    "ce:indexed-name": "Eich T."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Lorant T, Bengtsson M, Eich T,. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (Imlifidase) in chronic kidney disease patients. Am J Transplant 2018; 18: 2752-2762."
                    },
                    {
                        "ref-fulltext": "Huang E, Maldonado AQ, Kjellman C, Jordan SC,. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant 2022; 22: 691-697. The article summarized the implication of imlifidase in the treatment of antibody-mediated rejection (ABMR).",
                        "@reference-instance-id": "OB2BibRecID-944677102-c94f87e68b498a8f10c4977144a8fb8a-18",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85114751901",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "22"},
                                "pagerange": {
                                    "@first": "691",
                                    "@last": "697"
                                }
                            },
                            "ref-text": "The article summarized the implication of imlifidase in the treatment of antibody-mediated rejection (ABMR)",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Huang",
                                    "ce:indexed-name": "Huang E."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.Q.",
                                    "@_fa": "true",
                                    "ce:surname": "Maldonado",
                                    "ce:indexed-name": "Maldonado A.Q."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Kjellman",
                                    "ce:indexed-name": "Kjellman C."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "S.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Jordan",
                                    "ce:indexed-name": "Jordan S.C."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Huang E, Maldonado AQ, Kjellman C, Jordan SC,. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant 2022; 22: 691-697. The article summarized the implication of imlifidase in the treatment of antibody-mediated rejection (ABMR)."
                    },
                    {
                        "ref-fulltext": "Jarnum S, Bockermann R, Runstrom A,. The bacterial enzyme IdeS cleaves the IgG-Type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation. J Immunol 2015; 195: 5592-5601.",
                        "@reference-instance-id": "OB2BibRecID-944677102-83cbc3751cf4bcccd5e6a97869e7b349-19",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "The bacterial enzyme IdeS cleaves the IgG-Type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84958259121",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "195"},
                                "pagerange": {
                                    "@first": "5592",
                                    "@last": "5601"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Jarnum",
                                    "ce:indexed-name": "Jarnum S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Bockermann",
                                    "ce:indexed-name": "Bockermann R."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Runstrom",
                                    "ce:indexed-name": "Runstrom A."
                                }
                            ]},
                            "ref-sourcetitle": "J Immunol"
                        },
                        "ce:source-text": "Jarnum S, Bockermann R, Runstrom A,. The bacterial enzyme IdeS cleaves the IgG-Type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation. J Immunol 2015; 195: 5592-5601."
                    },
                    {
                        "ref-fulltext": "Jordan SC, Lorant T, Choi J,. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377: 442-453.",
                        "@reference-instance-id": "OB2BibRecID-944677102-7747476ef891355529171d2b9da2d134-20",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "IgG endopeptidase in highly sensitized patients undergoing transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85026751789",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "377"},
                                "pagerange": {
                                    "@first": "442",
                                    "@last": "453"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Jordan",
                                    "ce:indexed-name": "Jordan S.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Lorant",
                                    "ce:indexed-name": "Lorant T."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Choi",
                                    "ce:indexed-name": "Choi J."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Jordan SC, Lorant T, Choi J,. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377: 442-453."
                    },
                    {
                        "ref-fulltext": "Jordan SC, Legendre C, Desai NM,. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international Phase 2 trial (Highdes). Transplantation 2021; 105: 1808-1817.",
                        "@reference-instance-id": "OB2BibRecID-944677102-7943da73d26ca47839b2cc4b8883005c-21",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international Phase 2 trial (Highdes)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85111338197",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "105"},
                                "pagerange": {
                                    "@first": "1808",
                                    "@last": "1817"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Jordan",
                                    "ce:indexed-name": "Jordan S.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Legendre",
                                    "ce:indexed-name": "Legendre C."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "N.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Desai",
                                    "ce:indexed-name": "Desai N.M."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Jordan SC, Legendre C, Desai NM,. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international Phase 2 trial (Highdes). Transplantation 2021; 105: 1808-1817."
                    },
                    {
                        "ref-fulltext": "Al-Salama ZT,. Imlifidase: first approval. Drugs 2020; 80: 1859-1864.",
                        "@reference-instance-id": "OB2BibRecID-944677102-0df25c6487d5f1be568d0152f728a555-22",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Imlifidase: First approval"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85095606600",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "80"},
                                "pagerange": {
                                    "@first": "1859",
                                    "@last": "1864"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "Z.T.",
                                "@_fa": "true",
                                "ce:surname": "Al-Salama",
                                "ce:indexed-name": "Al-Salama Z.T."
                            }]},
                            "ref-sourcetitle": "Drugs"
                        },
                        "ce:source-text": "Al-Salama ZT,. Imlifidase: first approval. Drugs 2020; 80: 1859-1864."
                    },
                    {
                        "ref-fulltext": "Jordan SC, Choi J, Kim I,. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation 2017; 101: 32-44.",
                        "@reference-instance-id": "OB2BibRecID-944677102-259ef7f38d192e0628e5b2b95f1bccfe-23",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84983527075",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "101"},
                                "pagerange": {
                                    "@first": "32",
                                    "@last": "44"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Jordan",
                                    "ce:indexed-name": "Jordan S.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Choi",
                                    "ce:indexed-name": "Choi J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Kim",
                                    "ce:indexed-name": "Kim I."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Jordan SC, Choi J, Kim I,. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation 2017; 101: 32-44."
                    },
                    {
                        "ref-fulltext": "Choi J, Aubert O, Vo A,. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017; 17: 2381-2389.",
                        "@reference-instance-id": "OB2BibRecID-944677102-0741dec29e173f29685d3129b8c0cba5-24",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028420640",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "17"},
                                "pagerange": {
                                    "@first": "2381",
                                    "@last": "2389"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Choi",
                                    "ce:indexed-name": "Choi J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "O.",
                                    "@_fa": "true",
                                    "ce:surname": "Aubert",
                                    "ce:indexed-name": "Aubert O."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Vo",
                                    "ce:indexed-name": "Vo A."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Choi J, Aubert O, Vo A,. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017; 17: 2381-2389."
                    },
                    {
                        "ref-fulltext": "Massat M, Congy-Jolivet N, Hebral AL,. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 2021; 21: 1641-1649.",
                        "@reference-instance-id": "OB2BibRecID-944677102-233c9222705c502e2fc7a47af281f325-25",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85097518469",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "21"},
                                "pagerange": {
                                    "@first": "1641",
                                    "@last": "1649"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Massat",
                                    "ce:indexed-name": "Massat M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Congy-Jolivet",
                                    "ce:indexed-name": "Congy-Jolivet N."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Hebral",
                                    "ce:indexed-name": "Hebral A.L."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Massat M, Congy-Jolivet N, Hebral AL,. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 2021; 21: 1641-1649."
                    },
                    {
                        "ref-fulltext": "Lavacca A, Presta R, Gai C,. Early effects of first-line treatment with antiinterleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant 2020; 34: e13908.",
                        "@reference-instance-id": "OB2BibRecID-944677102-4d2529b28f5b270c46717fdcf6dd5430-26",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Early effects of first-line treatment with antiinterleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85086437349",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "34"},
                                "pagerange": {"@first": "e13908"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Lavacca",
                                    "ce:indexed-name": "Lavacca A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Presta",
                                    "ce:indexed-name": "Presta R."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Gai",
                                    "ce:indexed-name": "Gai C."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Transplant"
                        },
                        "ce:source-text": "Lavacca A, Presta R, Gai C,. Early effects of first-line treatment with antiinterleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant 2020; 34: e13908."
                    },
                    {
                        "ref-fulltext": "Pottebaum AA, Venkatachalam K, Liu C,. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct 2020; 6: e543.",
                        "@reference-instance-id": "OB2BibRecID-944677102-5f07f670553996157546021afe31a47f-27",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85083718159",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "6"},
                                "pagerange": {"@first": "e543"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Pottebaum",
                                    "ce:indexed-name": "Pottebaum A.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Venkatachalam",
                                    "ce:indexed-name": "Venkatachalam K."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Liu",
                                    "ce:indexed-name": "Liu C."
                                }
                            ]},
                            "ref-sourcetitle": "Transplant Direct"
                        },
                        "ce:source-text": "Pottebaum AA, Venkatachalam K, Liu C,. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct 2020; 6: e543."
                    },
                    {
                        "ref-fulltext": "Doberer K, Duerr M, Halloran PF,. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 2021; 32: 708-722. The study is the first randomized controlled study of anti-IL-6 antibody for the treatment of ABMR.",
                        "@reference-instance-id": "OB2BibRecID-944677102-563fd330fd501b95b048b9bcb2f7a61c-28",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85102134435",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "32"},
                                "pagerange": {
                                    "@first": "708",
                                    "@last": "722"
                                }
                            },
                            "ref-text": "The study is the first randomized controlled study of anti-IL-6 antibody for the treatment of ABMR",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Doberer",
                                    "ce:indexed-name": "Doberer K."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Duerr",
                                    "ce:indexed-name": "Duerr M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "P.F.",
                                    "@_fa": "true",
                                    "ce:surname": "Halloran",
                                    "ce:indexed-name": "Halloran P.F."
                                }
                            ]},
                            "ref-sourcetitle": "J Am Soc Nephrol"
                        },
                        "ce:source-text": "Doberer K, Duerr M, Halloran PF,. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 2021; 32: 708-722. The study is the first randomized controlled study of anti-IL-6 antibody for the treatment of ABMR."
                    },
                    {
                        "ref-fulltext": "Callemeyn J, Lamarthee B, Koenig A,. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int 2022; 101: 692-710. The article intensively reviewed the recent findings of allorecognition and the mechanism of rejection.",
                        "@reference-instance-id": "OB2BibRecID-944677102-724d4e7eebb824d37553b6edf46c369e-29",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Allorecognition and the spectrum of kidney transplant rejection"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85125499993",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "101"},
                                "pagerange": {
                                    "@first": "692",
                                    "@last": "710"
                                }
                            },
                            "ref-text": "The article intensively reviewed the recent findings of allorecognition and the mechanism of rejection",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Callemeyn",
                                    "ce:indexed-name": "Callemeyn J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Lamarthee",
                                    "ce:indexed-name": "Lamarthee B."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Koenig",
                                    "ce:indexed-name": "Koenig A."
                                }
                            ]},
                            "ref-sourcetitle": "Kidney Int"
                        },
                        "ce:source-text": "Callemeyn J, Lamarthee B, Koenig A,. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int 2022; 101: 692-710. The article intensively reviewed the recent findings of allorecognition and the mechanism of rejection."
                    },
                    {
                        "ref-fulltext": "Petrucci MT, Vozella F,. The anti-CD38 antibody therapy in multiple myeloma. Cells 2019; 8: 1629.",
                        "@reference-instance-id": "OB2BibRecID-944677102-fd3e74f1be9584b1fb7d35c0aacbf35c-30",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The anti-CD38 antibody therapy in multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85083329326",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {"@first": "1629"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.T.",
                                    "@_fa": "true",
                                    "ce:surname": "Petrucci",
                                    "ce:indexed-name": "Petrucci M.T."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "F.",
                                    "@_fa": "true",
                                    "ce:surname": "Vozella",
                                    "ce:indexed-name": "Vozella F."
                                }
                            ]},
                            "ref-sourcetitle": "Cells"
                        },
                        "ce:source-text": "Petrucci MT, Vozella F,. The anti-CD38 antibody therapy in multiple myeloma. Cells 2019; 8: 1629."
                    },
                    {
                        "ref-fulltext": "Doberer K, Klager J, Gualdoni GA,. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 2021; 105: 451-457.",
                        "@reference-instance-id": "OB2BibRecID-944677102-ad738623be239d86274dcfb7bd389806-31",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85100359467",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "105"},
                                "pagerange": {
                                    "@first": "451",
                                    "@last": "457"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Doberer",
                                    "ce:indexed-name": "Doberer K."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Klager",
                                    "ce:indexed-name": "Klager J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "G.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Gualdoni",
                                    "ce:indexed-name": "Gualdoni G.A."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Doberer K, Klager J, Gualdoni GA,. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 2021; 105: 451-457."
                    },
                    {
                        "ref-fulltext": "Mayer KA, Budde K, Halloran PF,. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials 2022; 23: 270.",
                        "@reference-instance-id": "OB2BibRecID-944677102-9c98fff4f91ed946ead5b27ade758ffd-32",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: Study protocol for a phase 2 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85127881251",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "23"},
                                "pagerange": {"@first": "270"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Mayer",
                                    "ce:indexed-name": "Mayer K.A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Budde",
                                    "ce:indexed-name": "Budde K."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "P.F.",
                                    "@_fa": "true",
                                    "ce:surname": "Halloran",
                                    "ce:indexed-name": "Halloran P.F."
                                }
                            ]},
                            "ref-sourcetitle": "Trials"
                        },
                        "ce:source-text": "Mayer KA, Budde K, Halloran PF,. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials 2022; 23: 270."
                    },
                    {
                        "ref-fulltext": "Joher N, Matignon M, Grimbert P,. HLA desensitization in solid organ transplantation: anti-CD38 to across the immunological barriers. Front Immunol 2021; 12: 688301.",
                        "@reference-instance-id": "OB2BibRecID-944677102-916edc7cc963901f1754c6327755b83b-33",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "HLA desensitization in solid organ transplantation: Anti-CD38 to across the immunological barriers"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85107197626",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {"@first": "688301"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "N.",
                                    "@_fa": "true",
                                    "ce:surname": "Joher",
                                    "ce:indexed-name": "Joher N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Matignon",
                                    "ce:indexed-name": "Matignon M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Grimbert",
                                    "ce:indexed-name": "Grimbert P."
                                }
                            ]},
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Joher N, Matignon M, Grimbert P,. HLA desensitization in solid organ transplantation: anti-CD38 to across the immunological barriers. Front Immunol 2021; 12: 688301."
                    },
                    {
                        "ref-fulltext": "Scurt FG, Ewert L, Mertens PR,. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet 2019; 393: 2059-2072.",
                        "@reference-instance-id": "OB2BibRecID-944677102-7c019f721660a0f869faa580332e27c5-34",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Clinical outcomes after ABO-incompatible renal transplantation: A systematic review and meta-analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85065640818",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "393"},
                                "pagerange": {
                                    "@first": "2059",
                                    "@last": "2072"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "F.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Scurt",
                                    "ce:indexed-name": "Scurt F.G."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Ewert",
                                    "ce:indexed-name": "Ewert L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "P.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Mertens",
                                    "ce:indexed-name": "Mertens P.R."
                                }
                            ]},
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Scurt FG, Ewert L, Mertens PR,. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet 2019; 393: 2059-2072."
                    },
                    {
                        "ref-fulltext": "de Weerd AE, van den Brand J, Bouwsma H,. ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis. Transpl Int 2021; 34: 2706-2719. The multicenter Dutch study reported the experiences of transplant centers using different preconditioning strategies for ABO-incompatible kidney transplantation.",
                        "@reference-instance-id": "OB2BibRecID-944677102-bd7b2bcb7fb94b91845959e617659a82-35",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: A propensity-matched analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85118866017",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "34"},
                                "pagerange": {
                                    "@first": "2706",
                                    "@last": "2719"
                                }
                            },
                            "ref-text": "The multicenter Dutch study reported the experiences of transplant centers using different preconditioning strategies for ABO-incompatible kidney transplantation",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.E.",
                                    "@_fa": "true",
                                    "ce:surname": "De Weerd",
                                    "ce:indexed-name": "De Weerd A.E."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Van Den Brand",
                                    "ce:indexed-name": "Van Den Brand J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Bouwsma",
                                    "ce:indexed-name": "Bouwsma H."
                                }
                            ]},
                            "ref-sourcetitle": "Transpl Int"
                        },
                        "ce:source-text": "de Weerd AE, van den Brand J, Bouwsma H,. ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis. Transpl Int 2021; 34: 2706-2719. The multicenter Dutch study reported the experiences of transplant centers using different preconditioning strategies for ABO-incompatible kidney transplantation."
                    },
                    {
                        "ref-fulltext": "Sonnenday CJ, Warren DS, Cooper M,. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322.",
                        "@reference-instance-id": "OB2BibRecID-944677102-861b810f63e47581733206ae7ec98e22-36",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2004"},
                            "ref-title": {"ref-titletext": "Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "3042746307",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {
                                    "@first": "1315",
                                    "@last": "1322"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Sonnenday",
                                    "ce:indexed-name": "Sonnenday C.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Warren",
                                    "ce:indexed-name": "Warren D.S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Cooper",
                                    "ce:indexed-name": "Cooper M."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Sonnenday CJ, Warren DS, Cooper M,. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322."
                    },
                    {
                        "ref-fulltext": "Tyden G, Kumlien G, Genberg H,. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148.",
                        "@reference-instance-id": "OB2BibRecID-944677102-0204e11c61cced316e1c88ce045b4595-37",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2005"},
                            "ref-title": {"ref-titletext": "ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab"},
                            "refd-itemidlist": {"itemid": {
                                "$": "11844276631",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "145",
                                    "@last": "148"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Tyden",
                                    "ce:indexed-name": "Tyden G."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "G.",
                                    "@_fa": "true",
                                    "ce:surname": "Kumlien",
                                    "ce:indexed-name": "Kumlien G."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Genberg",
                                    "ce:indexed-name": "Genberg H."
                                }
                            ]},
                            "ref-sourcetitle": "Am J Transplant"
                        },
                        "ce:source-text": "Tyden G, Kumlien G, Genberg H,. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148."
                    },
                    {
                        "ref-fulltext": "Tanabe K,. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84: S4-7.",
                        "@reference-instance-id": "OB2BibRecID-944677102-9b5e3c600b4ead03506f12d7eb83ccf5-38",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-title": {"ref-titletext": "Japanese experience of ABO-incompatible living kidney transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "37549071886",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "84"},
                                "pagerange": {
                                    "@first": "S4",
                                    "@last": "S7"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "K.",
                                "@_fa": "true",
                                "ce:surname": "Tanabe",
                                "ce:indexed-name": "Tanabe K."
                            }]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Tanabe K,. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84: S4-7."
                    },
                    {
                        "ref-fulltext": "Shinoda K, Hyodo Y, Oguchi H,. Outcome of ABO-incompatible kidney transplantation using a modified desensitization protocol without plasmapheresis. Int J Urol 2022; 29: 1017-1025. The work assessed the 1-year graft survival among ABOi kidney transplant recipients who had modified desensitization without plasmapheresis. Among those with low titer of ABO-Ab (less than 1 : 64), it remains inconclusive whether pretransplant plasmapheresis should be omitted or not.",
                        "@reference-instance-id": "OB2BibRecID-944677102-b77c4ffe0db518049ec9e753d3bc8957-39",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Outcome of ABO-incompatible kidney transplantation using a modified desensitization protocol without plasmapheresis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85131623317",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "29"},
                                "pagerange": {
                                    "@first": "1017",
                                    "@last": "1025"
                                }
                            },
                            "ref-text": "The work assessed the 1-year graft survival among ABOi kidney transplant recipients who had modified desensitization without plasmapheresis. Among those with low titer of ABO-Ab (less than 1 : 64), it remains inconclusive whether pretransplant plasmapheresis should be omitted or not",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Shinoda",
                                    "ce:indexed-name": "Shinoda K."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "Y.",
                                    "@_fa": "true",
                                    "ce:surname": "Hyodo",
                                    "ce:indexed-name": "Hyodo Y."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Oguchi",
                                    "ce:indexed-name": "Oguchi H."
                                }
                            ]},
                            "ref-sourcetitle": "Int J Urol"
                        },
                        "ce:source-text": "Shinoda K, Hyodo Y, Oguchi H,. Outcome of ABO-incompatible kidney transplantation using a modified desensitization protocol without plasmapheresis. Int J Urol 2022; 29: 1017-1025. The work assessed the 1-year graft survival among ABOi kidney transplant recipients who had modified desensitization without plasmapheresis. Among those with low titer of ABO-Ab (less than 1 : 64), it remains inconclusive whether pretransplant plasmapheresis should be omitted or not."
                    },
                    {
                        "ref-fulltext": "Lee HR, Kim K, Lee SW,. Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: a network meta-analysis. Medicine (Baltimore) 2021; 100: e24853. The study assessed which dose of rituximab should be used for ABOi KT. It was found that 200 mg per patient is very safe and effective. However, the currently available data may not be enough to make a firm conclusion.",
                        "@reference-instance-id": "OB2BibRecID-944677102-1f5d39e5ec53d1a39a60e2effe46ef76-40",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85103072188",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "100"},
                                "pagerange": {"@first": "e24853"}
                            },
                            "ref-text": "The study assessed which dose of rituximab should be used for ABOi KT. It was found that 200 mg per patient is very safe and effective. However, the currently available data may not be enough to make a firm conclusion",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Lee",
                                    "ce:indexed-name": "Lee H.R."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "Kim",
                                    "ce:indexed-name": "Kim K."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.W.",
                                    "@_fa": "true",
                                    "ce:surname": "Lee",
                                    "ce:indexed-name": "Lee S.W."
                                }
                            ]},
                            "ref-sourcetitle": "Medicine (Baltimore)"
                        },
                        "ce:source-text": "Lee HR, Kim K, Lee SW,. Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: a network meta-analysis. Medicine (Baltimore) 2021; 100: e24853. The study assessed which dose of rituximab should be used for ABOi KT. It was found that 200 mg per patient is very safe and effective. However, the currently available data may not be enough to make a firm conclusion."
                    },
                    {
                        "ref-fulltext": "Kim HJ, Kim JS, Yang JJ,. Outcome of ABO-incompatible kidney transplantation according to ABO type of transfused plasma: comparative analysis between 'Universal' AB and donor-type plasma. Lab Med 2022; 53: 369-375. The article compared the use of universal AB transfusion versus donor-type plasma transfusion in ABOi kidney transplantation. Theoretically, both types of plasma could be used during the perioperative period. However, AB type is the universal plasma for all types of transfusion. The availability of plasma in the inventory is also another important factor that can affect which type of blood product can be used for the transplantation.",
                        "@reference-instance-id": "OB2BibRecID-944677102-e5cb9dcbe943a09bd0624caec7b5f90f-41",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Outcome of ABO-incompatible kidney transplantation according to ABO type of transfused plasma: Comparative analysis between 'Universal' AB and donor-type plasma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85134083600",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "53"},
                                "pagerange": {
                                    "@first": "369",
                                    "@last": "375"
                                }
                            },
                            "ref-text": "The article compared the use of universal AB transfusion versus donor-type plasma transfusion in ABOi kidney transplantation. Theoretically, both types of plasma could be used during the perioperative period. However, AB type is the universal plasma for all types of transfusion. The availability of plasma in the inventory is also another important factor that can affect which type of blood product can be used for the transplantation",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Kim",
                                    "ce:indexed-name": "Kim H.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Kim",
                                    "ce:indexed-name": "Kim J.S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Yang",
                                    "ce:indexed-name": "Yang J.J."
                                }
                            ]},
                            "ref-sourcetitle": "Lab Med"
                        },
                        "ce:source-text": "Kim HJ, Kim JS, Yang JJ,. Outcome of ABO-incompatible kidney transplantation according to ABO type of transfused plasma: comparative analysis between 'Universal' AB and donor-type plasma. Lab Med 2022; 53: 369-375. The article compared the use of universal AB transfusion versus donor-type plasma transfusion in ABOi kidney transplantation. Theoretically, both types of plasma could be used during the perioperative period. However, AB type is the universal plasma for all types of transfusion. The availability of plasma in the inventory is also another important factor that can affect which type of blood product can be used for the transplantation."
                    },
                    {
                        "ref-fulltext": "Tasaki M, Tateno H, Sato T,. A novel method of CD31-combined ABO carbohydrate antigen microarray predicts acute antibody-mediated rejection in ABO-incompatible kidney transplantation. Transpl Int 2022; 35: 10248. The study developed a new method to detect A/B antibody bound to CD31 protein which is expressed on kidney epithelial cells. It was proposed that both CD31 and A/B antigen are more accurate in predicting ABMR. Due to the small sample size, the findings from this study are still questionable.",
                        "@reference-instance-id": "OB2BibRecID-944677102-f6dc6b299339b67fe681842698b019b0-42",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "A novel method of CD31-combined ABO carbohydrate antigen microarray predicts acute antibody-mediated rejection in ABO-incompatible kidney transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85127965751",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "35"},
                                "pagerange": {"@first": "10248"}
                            },
                            "ref-text": "The study developed a new method to detect A/B antibody bound to CD31 protein which is expressed on kidney epithelial cells. It was proposed that both CD31 and A/B antigen are more accurate in predicting ABMR. Due to the small sample size, the findings from this study are still questionable",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Tasaki",
                                    "ce:indexed-name": "Tasaki M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Tateno",
                                    "ce:indexed-name": "Tateno H."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Sato",
                                    "ce:indexed-name": "Sato T."
                                }
                            ]},
                            "ref-sourcetitle": "Transpl Int"
                        },
                        "ce:source-text": "Tasaki M, Tateno H, Sato T,. A novel method of CD31-combined ABO carbohydrate antigen microarray predicts acute antibody-mediated rejection in ABO-incompatible kidney transplantation. Transpl Int 2022; 35: 10248. The study developed a new method to detect A/B antibody bound to CD31 protein which is expressed on kidney epithelial cells. It was proposed that both CD31 and A/B antigen are more accurate in predicting ABMR. Due to the small sample size, the findings from this study are still questionable."
                    },
                    {
                        "ref-fulltext": "Hirzel C, Projer L, Atkinson A,. Infection risk in the first year after ABO-incompatible kidney transplantation: a nationwide prospective cohort study. Transplantation 2022; 106: 1875-1883. This is a multicenter national cohort that compared the first-year prevalence of infections between ABOi and ABOc kidney transplantation recipients. In this study, all of the patients received a similar preconditioning protocol including immuno-adsorption and Rituximab. Infection was 1.11 episode per patient-year in the ABOi group and was not different from the ABOc group.",
                        "@reference-instance-id": "OB2BibRecID-944677102-3e9d62f68128c55d9f72da7a0b75739d-43",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Infection risk in the first year after ABO-incompatible kidney transplantation: A nationwide prospective cohort study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85136891600",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "106"},
                                "pagerange": {
                                    "@first": "1875",
                                    "@last": "1883"
                                }
                            },
                            "ref-text": "This is a multicenter national cohort that compared the first-year prevalence of infections between ABOi and ABOc kidney transplantation recipients. In this study, all of the patients received a similar preconditioning protocol including immuno-adsorption and Rituximab. Infection was 1.11 episode per patient-year in the ABOi group and was not different from the ABOc group",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.",
                                    "@_fa": "true",
                                    "ce:surname": "Hirzel",
                                    "ce:indexed-name": "Hirzel C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Projer",
                                    "ce:indexed-name": "Projer L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Atkinson",
                                    "ce:indexed-name": "Atkinson A."
                                }
                            ]},
                            "ref-sourcetitle": "Transplantation"
                        },
                        "ce:source-text": "Hirzel C, Projer L, Atkinson A,. Infection risk in the first year after ABO-incompatible kidney transplantation: a nationwide prospective cohort study. Transplantation 2022; 106: 1875-1883. This is a multicenter national cohort that compared the first-year prevalence of infections between ABOi and ABOc kidney transplantation recipients. In this study, all of the patients received a similar preconditioning protocol including immuno-adsorption and Rituximab. Infection was 1.11 episode per patient-year in the ABOi group and was not different from the ABOc group."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85142940973",
        "dc:description": "Purpose of reviewAntibody-mediated rejection (ABMR) is an important barrier to achieve long-term kidney allograft survival. Human leukocyte antibody (HLA)-incompatibility and ABO-incompatibility are the two main mechanisms of ABMR. Nevertheless, the advances in managing ABMR have changed the paradigm for kidney transplantation. This review aimed to emphasize the HLA-incompatibility and ABO-incompatibility kidney transplant and update the management of ABMR.Recent findingsHLA-incompatibility kidney transplantation is a strong risk factor for ABMR. Donor-specific antibody (DSA) is a surrogate biomarker that prevents long-term allograft survival. The standard treatment for ABMR has unfavorable results. New drugs that target the B cell are a promising approach to treat ABMR. In the past, ABO-incompatibility kidney donor was an absolute contraindication but now, it is widely accepted as an alternative organ resource. The advancement of ABO antibody removal and B-cell depletion therapy has been successfully developed. ABO isoagglutination remains the main biomarker for monitoring ABMR during the transplantation process. C4d staining without inflammation of the kidney allograft is the marker for the accommodation process.SummaryWith the shortage of organ donors, transplant experts have expanded the organ resources and learned how to overcome the immunological barriers by using novel biomarkers and developing new treatments that support long-term graft survival.",
        "pubmed-id": "36250450",
        "prism:coverDate": "2023-01-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85142940973",
        "dc:creator": {"author": [{
            "ce:given-name": "Natavudh",
            "preferred-name": {
                "ce:given-name": "Natavudh",
                "ce:initials": "N.",
                "ce:surname": "Townamchai",
                "ce:indexed-name": "Townamchai N."
            },
            "@seq": "1",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                },
                {
                    "@id": "60022183",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
                }
            ],
            "ce:surname": "Townamchai",
            "@auid": "24588157900",
            "author-url": "https://api.elsevier.com/content/author/author_id/24588157900",
            "ce:indexed-name": "Townamchai N."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85142940973"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85142940973&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85142940973&origin=inward"
            }
        ],
        "source-id": "19849",
        "citedby-count": "0",
        "prism:volume": "32",
        "subtype": "re",
        "dc:title": "Updated management for antibody-mediated rejection: Opportunity to prolong kidney allograft survival",
        "openaccess": "0",
        "prism:issn": "14736543 10624821",
        "publishercopyright": "© 2023 Lippincott Williams and Wilkins. All rights reserved.",
        "prism:issueIdentifier": "1",
        "subtypeDescription": "Review",
        "prism:publicationName": "Current Opinion in Nephrology and Hypertension",
        "prism:pageRange": "13-19",
        "prism:endingPage": "19",
        "openaccessFlag": "false",
        "prism:doi": "10.1097/MNH.0000000000000843",
        "prism:startingPage": "13",
        "dc:identifier": "SCOPUS_ID:85142940973",
        "dc:publisher": "Lippincott Williams and Wilkins"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Allografts",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Biomarkers",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Graft Rejection",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Graft Survival",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Isoantibodies",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Kidney",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "ABO incompatibility"
        },
        {
            "@_fa": "true",
            "$": "antibody-mediated rejection"
        },
        {
            "@_fa": "true",
            "$": "antihuman leukocyte antigen"
        },
        {
            "@_fa": "true",
            "$": "donor-specific antihuman leukocyte antibody"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Medicine (all)",
        "@code": "2700",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Natavudh",
            "preferred-name": {
                "ce:given-name": "Natavudh",
                "ce:initials": "N.",
                "ce:surname": "Townamchai",
                "ce:indexed-name": "Townamchai N."
            },
            "@seq": "1",
            "ce:initials": "N.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                },
                {
                    "@id": "60022183",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
                }
            ],
            "ce:surname": "Townamchai",
            "@auid": "24588157900",
            "author-url": "https://api.elsevier.com/content/author/author_id/24588157900",
            "ce:indexed-name": "Townamchai N."
        },
        {
            "ce:given-name": "Yingyos",
            "preferred-name": {
                "ce:given-name": "Yingyos",
                "ce:initials": "Y.",
                "ce:surname": "Avihingsanon",
                "ce:indexed-name": "Avihingsanon Y."
            },
            "@seq": "2",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                },
                {
                    "@id": "60022183",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
                }
            ],
            "ce:surname": "Avihingsanon",
            "@auid": "57194864874",
            "author-url": "https://api.elsevier.com/content/author/author_id/57194864874",
            "ce:indexed-name": "Avihingsanon Y."
        }
    ]}
}}